17 July 2021 (Saturday) ASH Update

The American Society of Hematology sent an update on chronic leukaemia today. As always they focus on the clinical rather than the technical, but it is all good CPD…


Head-to-Head Trial Confirms Acalabrutinib’s Noninferiority to Ibrutinib in CLL
At EHA2021 Virtual, researchers presented results from the first head-to-head trial of BTK inhibitors in CLL, finding that acalabrutinib is noninferior to ibrutinib in terms of progression-free survival.
Exploring Venetoclax Plus Azacitidine in CMML and MPNs
Results from two recently published studies investigated the treatment combination in patients with chronic myelomonocytic leukemia and myeloproliferative neoplasms MPNs, finding that venetoclax plus azacitidine led to high response rates in these disease settings.
Evaluating Maintenance Therapy After Fixed-Duration Obinutuzumab Plus Venetoclax in CLL
For patients who are considered unfit for FCR chemotherapy, a fixed-duration regimen of venetoclax plus obinutuzumab followed by consolidation with venetoclax led to high rates of undetectable measurable residual disease, according to results presented at EHA2021 Virtual.


No comments:

Post a Comment